A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium-Reference-Cited by-同舟云学术

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium

Published:2015-11-10 Issue:11 Volume:113 Page:1534-1540
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Lheureux S,Oza A M,Laurie S A,Halford R,Jonker D,Chen E,Keller D,Bourade V,Wang L,Doyle L,Siu L L,Goel R

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2015343.pdf

Reference28 articles.

1. Aapro MS, Martin C, Hatty S (1998) Gemcitabine--a safety review. Anticancer Drugs 9 (3): 191–201.

2. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1944) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12 (8): 1535–1540.

3. Bookman MA (2005) Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer 15 (Suppl 1): 12–17.

4. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73 (1): 101–105.

5. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377 (9769): 914–923.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas;International Journal of Molecular Sciences;2022-12-30

2. Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma;Clinical Cancer Research;2022-05-18

3. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC);ESMO Open;2021-02

4. Anticancer Alkaloids: Molecular Mechanisms and Clinical Manifestations;Bioactive Natural Products for the Management of Cancer: from Bench to Bedside;2019

5. Inactivation of ATF‐2 enhances epithelial‐mesenchymal transition and gemcitabine sensitivity in human pancreatic cancer cells;Journal of Cellular Biochemistry;2018-10-26